Stephanie Burnett
Papers
1
Total Citations
31
H-Index
1
About
Stephanie Burnett is a leading clinical researcher in radiation oncology, with a primary focus on optimizing treatment strategies for localized prostate cancer. Her work centers on the comparative effectiveness and quality-of-life outcomes of stereotactic body radiotherapy (SBRT) versus surgery, addressing a critical gap in randomized evidence for early-stage disease. Burnett’s major contribution is her role as a key investigator in the landmark PACE-A trial, an international phase 3 randomized controlled trial that directly compares SBRT to radical prostatectomy. This study, cited 31 times in 2023 alone, provides the first high-level randomized data on patient-reported quality of life following these two common treatments, offering crucial insights for shared decision-making. Her research has helped establish SBRT as a viable, less invasive alternative to surgery, with implications for reducing treatment-related morbidity. Burnett’s work is notable for its rigorous trial design and patient-centered outcomes, influencing clinical guidelines and practice patterns in uro-oncology. Her contributions continue to shape the evidence base for prostate cancer management, making her a respected voice in the field.
Research Focus
Key Achievements
Top Papers
- 1